Generic heart medication shown to prolong ovarian cancer patients' survival

(University of Texas M. D. Anderson Cancer Center) In a first-of-its-kind study, researchers demonstrate a benefit in overall survival among epithelial ovarian cancer patients receiving generic heart medications known as beta-blockers. Survival was shown to be greatest among those prescribed first-generation nonselective beta-blockers. According to The University of Texas MD Anderson Cancer Center investigators, the drugs block the effects of stress pathways involved in tumor growth and spread.